Quick Answer
Spero Therapeutics, Inc. reported Diluted EPS of $0.15 per share for fiscal year 2025.
Spero Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.15 | +111.8% |
| 2024 | -$1.27 | -395.3% |
| 2023 | $0.43 | +135.0% |
| 2022 | -$1.23 | +57.7% |
| 2021 | -$2.91 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.13 | +59.4% | -333.3% |
| June 30, 2025 | -$0.03 | +90.9% | +88.0% |
| March 31, 2025 | -$0.25 | -4.2% | +21.9% |
| September 30, 2024 | -$0.32 | -433.3% | +3.0% |
| June 30, 2024 | -$0.33 | -43.5% | -37.5% |
| March 31, 2024 | -$0.24 | +4.0% | -300.0% |
| September 30, 2023 | -$0.06 | +81.8% | +73.9% |
| June 30, 2023 | -$0.23 | +73.6% | +8.0% |
- Spero Therapeutics, Inc. showed an increase of +111.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Spero Therapeutics, Inc.’s diluted eps has grown by 105.2% (from $2.91 per share (loss) to $0.15 per share).
- The most recent figure is from Spero Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: